Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer lymphoma and melanoma

Journal of Nuclear Medicine

Volumn 40, Issue 4, 1999, Pages 591-603

  Delbeke, Dominique ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Emission CT; Fluorine; Glucose; Metabolism; Neoplasms

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; BRAIN METABOLISM; BRAIN TUMOR; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; GLUCOSE METABOLISM; HUMAN; INTESTINE LYMPHOMA; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL;

ARTIFACTS; BRAIN NEOPLASMS; COLORECTAL NEOPLASMS; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; MELANOMA; NEOPLASM STAGING; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032962081     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Warburg O. Versuche und uberledbeudem carcinomgewebe (methoden). Biochem Z. 1923;142:317-333.
2. Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by rats or src oncogenes. Science. 1987;235:1492-1495.
3. Monakhov NK, Neistadt EI, Shaylovskii MM. et al. Physiochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst. 1978;61:27-34.
4. Knox WE, Jamdar SC, Davis PA, Hexokinase, differentiation and growth rates of transplanted tumors. Cancer Res. 1970;30:2240-2244.
5. 18F]: nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670-675.
6. 18F]2-deoxy-2-fluoro-D-glucose. J Nucl Med. 1978;19:1154-1161.
7. Kim CK, Gupta NC, Chandramouli B, et al. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med. 1994;35:164-167.
8. Zasadny KR, Wahl RL. Standard uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993;189:847-850.
9. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med. 1993;34:1-6.
10. Langen KJ, Braun U, Kops ER, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993;34:355-359.
11. Diedrichs C, Staib L, Glatting G, Beger HG, Reske SN, FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl MeD. 1998;39:1030-1033.
12. Cook GJR, Fogelman I, MaisEy MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308-314.
13. Engel H, Steinert H, Buck A, Berthold T, Boni RAH, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med. 1996;37:441-446.
14. Bakheet SM, Powe J. Benign causes of 18-FDG uptake on whole-body imaging. Semin Nucl Med. 1998;28:352-358.
15. 18F]-fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology. 1982; 144:885-889.
16. 18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323-1329.
17. Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. 1985;62:816-822.
18. Hoffman JM, Waskin HA, Schifter T, et al. FDG PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med. 1993;34:567-575.
19. Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology. 1987;164:521-526.
20. Borbely K, Fulham MJ, Brooks RA, Di Chiro G. PET-fluorodeoxyglucose of cranial and spinal neuromas. J Nucl Med. 1992;33:1931-1934.
21. Griffeth LK, Rich KM, Dehdashti F, et al. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology. 1993;186:37-44.
22. De Souza B, Brunetti A, Fulham MJ, et al. Pituitary microadenoma: a PET study. Radiology. 1990;177:39-44.
23. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195:47-52.
24. Foster JH, Lundy J. Liver metastases. Curr Probl Surg. 1981;18:158-202.
25. Holm A, Bradley E, Aldrete J. Hepatic resection of metastases from colorectal carcinoma: morbidity, mortality and pattern of recurrence. Ann Surg. 1989;209: 428-434.
26. August DA, Ottow RT, Sugarbaker PH. Clinical perspectives on human colorectal cancer metastases. Cancer Metastasis Rev. 1984;3:303-324.
27. Hughes KS, Simon R, Songhorabodi S, et al. Resection of liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery. 1988;103:278-288.
28. Moertel CG, Fleming TR, McDonald JS, Haller DJ, Laurie JA, Tangen CA. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943-947.
29. Steele G Jr, Bleday R, Mayer R, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group protocol 6584. J Clin Oncol. 1991;9:1105-1112.
30. Moss AA. Imaging of colorectal carcinoma. Radiology. 1989;170:308-310.
31. Soyer P, Levesque M, Elias D, Zeitoun G, Roche A. Detection of liver metastases from colorectal cancer: comparison of intraoperative US and CT during arterial portography. Radiology. 1992;183:541-544.
32. Peterson MS, Baron RL, Dodd GD III, et al. Hepatic parenchymal perfusion detected with CTPA: imaging-pathologic correlation. Radiology. 1992;183:149-155.
33. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage metastatic colorectal carcinoma to the liver. Am J Surg. 1996;171:21-26.
34. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196-1201.
35. 18F]fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med. 1982;23:1133-1137.
36. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. Radiology. 1989;170:329-332.
37. Ito K, Kato T, Tadokoro M, et al. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology. 1992;182:549-552.
38. Gupta NC, Falk PM, Frank AL, Thorson AM, Firck MP, Bowman B. Preoperative staging of colorectal carcinoma using positron emission tomography. Nebr Med J. 1993;78:30-35.
39. Falk PM, Gupta NC, Thorson AG, et al. Positron emission tomography for preoperative staging of colorectal carcinoma. Dis Colon Rectum. 1994;37:153-156.
40. Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol. 1995;21:517-522.
41. Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with F-18-fluorodeosyglucose in management of recurrent colorectal cancer. Arch Surg. 1999:in press.
42. Ruhlmann J, Schomburg A, Bender H, et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum. 1997;40:1195-1204.
43. Kim EE, Chung SK, Haynie TP, et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. RadioGraphics. 1992;12:269-279.
44. Vogel SB, Drane WE, Ros PR, Kerns SR, Bland KI. Prediction of surgical resectability in patients with hepatic colorectal metastases. Ann Surg. 1994;219: 508-516.
45. 18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg. 1994;81:1666-1670.
46. 18F]fluorodeoxyglucose in identifying operable colorectal cancer. Arch Surg. 1996;131:703-707.
47. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulocytes studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
48. Gambhir SS, Valk P, Shepherd J, Hoh C, Allen M, Phelps ME. Cost effective analysis modeling of the role of FDG PET in the management of patients with recurrent colorectal cancer [abstract]. J Nucl Med. 1997;38:90P.
49. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med. 1991;31:1485-1490.
50. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14:700-708.
51. Vitola JV, Delbeke D, Meranze SG, Mazer MJ, Pinson CW. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer. 1996;78:2216-2222.
52. Joth G, Bonadonna G. Prognostic factors in Hodgkin's disease: implications for modern treatment. Anticancer Res. 1988;8:749-760.
53. Newman J, Francis IR, Kaminske MS, Wahl RL. Imaging of lymphoma with PET with 2-[f-18]-fluoro-2-deoxyglucose: correlation with CT. Radiology. 1994;190: 111-116.
54. Munker R, Stengel A, Stabler A, Hiller E, Brehm G. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Cancer. 1995;76:1460-1466.
55. Front D, Israel O, Epelbaum R, et al. Ga-67 SPECT before and after treatment of lymphoma. Radiology: 1990;175:515-519.
56. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med. 1987;28:288-292.
57. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med. 1991;32:686-691.
58. Okada J, Yoshikawa K, Imazeki K, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 1992;33:325-329.
59. Leskinen-Kallio S, Rudsalainen U, Nagren K, Teras M, Joensuu H. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med. 1991;32:1211-1218.
60. Lapela M, Leskinen S, Minn HR, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood. 1995;86:3522-3527.
61. Rodriguez M, Rehn S, Ahlström H, Sunolstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med. 1995;36: 1790-1796.
62. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med. 1997;38:343-348.
63. Moog F, Bangerter M, Diedrichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 1997;203:795-800.
64. Moog F, Bangerter M, Diedrichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 1998;206:475-481.
65. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340-3346.
66. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998;16:603-609.
67. Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med. 1998;25:721-728.
68. de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol. 1997;8(suppl 1):57-60.
69. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91:4464-4471.
70. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:391-399.
71. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluoro-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med. 1993;34:1420-1427.
72. Steinert HC, Huch-Boni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;195:705-709.
73. Boni R, Boni RA, Steinert H, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol. 1995;132:556-562.
74. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol. 1995;131:1394-1398.
75. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 1996;6:325-329.
76. Wagner JD, Schauwecker D, Hutchins G, Coleman JJ III. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol. 1997;64:181-189.
77. 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1998;82:1664-1671.
78. 18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol. 1998;16:1770-1776.
79. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg. 1998;227:764-769.
80. Steinert HC, Voellmy DR, Trachsel C, et al. Planar coincidence scintigraphy and PET in staging malignant melanoma. J Nucl Med. 1998;39:1892-1897.
81. Valk PE, Segall GM, Johnson DL, et al. Cost-effectiveness of whole-body FDG PET imaging in metastatic melanoma [abstract]. J Nucl Med. 1997;38:89P.